Klaus Peters

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Matti Lehtinen, Jorma Paavonen, Cosette M. Wheeler et al. · The Lancet Oncology · 2011 · 703 citations

Medicine, Gynecology, Oncology +15

Natural History of Progression of HPV Infection to Cervical Lesion or Clearance: Analysis of the Control Arm of the Large, Randomised PATRICIA Study

Unnop Jaisamrarn, Xavier Castellsagué, Suzanne M. Garland et al. · PLoS ONE · 2013 · 216 citations · Full text

Medicine, Oncology, Pathology +17

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule

Barbara Romanowski, Tino F. Schwarz, Linda M. Ferguson et al. · Human Vaccines · 2011 · 194 citations · Full text

Veterinary Medicine, Immunology, Oncology +13

Prior human papillomavirus‐16/18 AS04‐adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: <i>Post‐hoc</i> analysis from a randomized controlled trial

Suzanne M. Garland, Jorma Paavonen, Unnop Jaisamrarn et al. · International Journal of Cancer · 2016 · 102 citations · Full text

Medicine, Gynecology, Oncology +17

Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination

Barbara Romanowski, Tino F. Schwarz, Linda M. Ferguson et al. · Human Vaccines & Immunotherapeutics · 2014 · 99 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17